Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 13Myeloid 7Thoracic 3Plasma cell 2Lymphoid 2Head & Neck 2Breast 2Sarcoma 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 17Lung Neoplasms 5Myelodysplastic Syndromes 4Prostatic Neoplasms 3Ovarian Neoplasms 3Neoplasms 3Multiple Myeloma 3Lymphoma, Non-Hodgkin 3Lymphoma 3Leukemia, Myeloid, Acute 3Leukemia 3Urinary Bladder Neoplasms 2Small Cell Lung Carcinoma 2Sarcoma 2Primary Myelofibrosis 2Lymphoma, Large B-Cell, Diffuse 2Hematologic Neoplasms 2Glioblastoma 2Breast Neoplasms 2Tumor Virus Infections 1Thyroid Neoplasms 1Testicular Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Recurrence 1Peritoneal Neoplasms 1Pathologic Complete Response 1Pancreatic Neoplasms 1Osteosarcoma 1Neoplasms, Plasma Cell 1

Interventions

pembrolizumab 61Carboplatin 44Pemetrexed 31Paclitaxel 31Docetaxel 31Cisplatin 27Gemcitabine 24Nivolumab 23Erlotinib Hydrochloride 21Bevacizumab 18Ipilimumab 11osimertinib 10Drug Therapy 10atezolizumab 9Radiosurgery 9Cyclophosphamide 9Cetuximab 9Blood Specimen Collection 9durvalumab 8cemiplimab 8Radiotherapy 8budigalimab 7Fluorouracil 7Dexamethasone 7trametinib 6fludarabine 6dostarlimab 6avelumab 6Taxes 6130-nm albumin-bound paclitaxel 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Neoplasms × Azacitidine × Thoracic × Clear all
NCT02250326 2024-09-19

abound2L+

Celgene

Phase 2 Completed
240 enrolled 23 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT02223052 2020-05-12

Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies

Celgene

Phase 1 Completed
89 enrolled
BreastCNSDermatologicGenitourinaryGynecologicHead & NeckLymphoidMyeloidOther hematologic neoplasmPlasma cellSarcomaThoracic

Urinary Bladder Neoplasms, Bone Neoplasms, Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Glioblastoma, Hodgkin Disease, Kidney Neoplasms, Leukemia, Lung Neoplasms, Lymphoma, Lymphoma, Non-Hodgkin, Melanoma, Multiple Myeloma, Myelodysplastic Syndromes, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Osteosarcoma, Skin Neoplasms, Testicular Neoplasms, Thyroid Neoplasms, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Small Cell Lung Carcinoma

NCT01545947 2019-11-12

Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer

Celgene

Phase 1 Completed
76 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡